Highly multiplex panels used to interrogate diverse immune populations and immuno-modulatory targets
Hear Dr. Kurt Schalper describe how research performed at the Translational Immuno-Oncology Laboratory at Yale Cancer Center uses Imaging Mass Cytometry™ (IMC™) as one way to open new opportunities for biomarker discovery and identification of targets that can lead to patient selection for novel immunostimulatory therapies.
In this recorded webinar, Schalper discusses:
- how his group deciphers the tumor microenvironment and its role in immuno-oncology using highly multiplexed panels
- strategies for validation of multiplexing panels to interrogate diverse tumor and immune cell populations
- the evaluation of antitumor immune responses and biomarker discovery
- results from immunoprofiling with Imaging Mass Cytometry to uncover the immune composition of human non-small cell lung cancer (NSCLC).
Please join us for the webinar and an in-depth Q&A session that follows.
Kurt Schalper, MD, PhD
Assistant Professor of Pathology and Medicine (Medical Oncology)
Director Translational Immuno-Oncology Laboratory
Yale Cancer Center
For Research Use Only. Not for use in diagnostic procedures.